CJC-1295 (No Dac)/Ipamorelin Blend
Overview
Research-use GHRH analogue and ghrelin receptor agonist blend supplied for studies of somatotropic-axis and GH/IGF-1 pathway models.
- Concentration
- 10 mg / 10 mg
- Stock
- In stock
Product details
CJC-1295 (No DAC)/Ipamorelin Blend combines a GHRH analogue with a ghrelin receptor agonist for somatotropic-axis research models. Pattern lists this material for controlled laboratory research.
Research Targets: GHRH receptor signaling, ghrelin receptor/GHS-R1a signaling, pituitary somatotroph pathway models.
Key Feature: Dual-pathway secretagogue research blend for coordinated endocrine signaling studies.
Research Focus Areas: Growth hormone pulse dynamics, IGF-1 pathway signaling, endocrine feedback, metabolic pathway studies.
Common Models: Pituitary cell assays, rodent endocrine models, metabolic signaling studies.
Mechanistic Interests: cAMP signaling, calcium mobilization, somatotroph activation, hypothalamic-pituitary axis dynamics.
Use Boundary: Research use only; not for human or veterinary use; no diagnostic, therapeutic, or consumption use is implied.
Product documentation
Certificate of Analysis
CJC-1295 with DAC
Review the public certificate available for this product before creating an account or checking out.
Research context
Peptide guide
Open full guide- Guide profile
- GHRH Analog and Selective GHRP Combination
- Composition
- Research combination pairing a GHRH analog, usually CJC-1295 or modified GRF 1-29, with the selective ghrelin-receptor agonist ipamorelin
- Discovery
- The pairing comes from growth-hormone secretagogue research that combines hypothalamic GHRH signaling with ghrelin-receptor signaling.
- Research scope
- Combination rationale is mechanistic: simultaneous GHRH and GHSR stimulation can produce synergistic GH release, but standardized human trials of commercial CJC/ipamorelin blends are limited
- Regulatory status
- Research-only/off-label; individual components are not approved for general wellness or routine aging use
Safety context
- Active malignancy or unresolved cancer-risk concerns
- Uncontrolled diabetes or significant insulin resistance without medical oversight
- Pregnancy or breastfeeding
Research-use notice: Use medical supervision and lab monitoring for any clinical decision-making.
Full guide includes 10 reference entries.
One kit adds 10 vials to checkout.